Arunachal govt inks agreement for Rs 13,000cr hydropower project in Lohit basin
时间:2024-06-26 17:46:53 阅读(143)
he Arunachal Pradesh government on Saturday signed an agreement with the Tehri Hydropower Development Corporation India Ltd (THDCIL) for developing the 1,200-mw Kalai-II hydroelectric project in the Lohit river basin for Rs 13,000 crore. State Hydropower Commissioner Ankur Garg and THDCIL’s director (technical) Bhupender Gupta signed the agreement on behalf of the two sides. Chief Secretary Dharmendra presided over the programme.
In August, the state government signed agreements with three central PSUs — NHPC, SJVN and NEEPCO — for developing 12 hydropower projects, having a combined capacity of 11,517 MW, in Subansiri, Dibang and Siang basins. With the allotment of the Kalai-II project to THDCIL, the government concluded agreements for 13 projects with a total capacity of 12,717 MW in this calendar year.
Deputy Chief Minister Chowna Mein said the project will create historic development and employment opportunities in the Lohit basin area.”The state government will have 26 per cent equity in the project. The dividend from this equity participation will further augment the state’s earnings,” Mein, who also holds the power and hydropower portfolios, said.
Chief Minister Pema Khandu thanked Prime Minister Narendra Modi and Union Power Minister RK Singh for their support towards restarting the project. He said the state was committed to ensuring the full realisation of its hydropower potential for meeting the energy needs of the country.
上一篇:BSE to divest 2
猜你喜欢
- Adani Enterprises share price jumps 4%, firm joins hands with TotalEnergies to invest $50 bn in green hydrogen
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- TERM RETURN OF PREMIUM PLANS- Get cover & also your premiums back
- Buy IndusInd Bank, Maruti Suzuki, other stocks to pocket gains; Nifty support at 18300, likely to hit 18600
- Thousands evacuated as devastating floods hit northeastern China – In pics
- Blackstone’s Nexus Select Trust REIT IPO- Price band set at Rs 95-100 per unit; Rs 3200 cr issue opens 9 May
- BPCL, Grasim Industries among 223 stocks to hit
- Top stocks in which promoters increased stake by more than 1% in Q2 FY24
- Adani FPO delay- Bankers mull extending date, cutting offer price amid Hindenburg allegations